Teresa Troiani

Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial

Andrea Sartore‐Bianchi, Livio Trusolino, Cosimo Martino et al. · The Lancet Oncology · 2016 · 984 citations · Full text

Oncology, Medicine, Pathology +5

Antitumor Activity of ZD6474, a Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Human Cancer Cells with Acquired Resistance to Antiepidermal Growth Factor Receptor Therapy

Fortunato Ciardiello, Roberto Bianco, Roberta Caputo et al. · Clinical Cancer Research · 2004 · 346 citations

ESMO recommendations on the standard methods to detect NTRK fusions in daily practice and clinical research

Caterina Marchiò, Maurizio Scaltriti, Marc Ladanyi et al. · Annals of Oncology · 2019 · 345 citations · Full text

Esmo Recommendations, Medicine, Ntrk Fusions +5

Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase.

Fortunato Ciardiello, Rosa Caputo, Vincenzo Damiano et al. · PubMed · 2003 · 329 citations

Global cancer control: responding to the growing burden, rising costs and inequalities in access

Gerald W. Prager, Sofía Braga, Branislav Bystrický et al. · ESMO Open · 2018 · 298 citations · Full text